MedTrace Logo

Novel ERG for Detection of Hydroxychloroquine Retinopathy

NCT06035887 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 140

Last updated 2025-08-06

No results posted yet for this study

Summary

The purpose of the study is to investigate novel electroretinography (ERG) devices in the detection of hydroxychloroquine retinopathy. Two devices (the RETEval full-field and flicker ERG and UTAS multifocal ERG) will be evaluated in this study, comparing device outputs to standard of care screening tests, in groups of participants characterised by presence or absence of hydroxychloroquine-related retinopathy.

Conditions

  • Hydroxychloroquine Retinopathy

Interventions

DIAGNOSTIC_TEST

Hand-Held Full-Field Skin-Electrode Electroretinography (Device to be evaluated)

RETEval Complete hand-held electroretinogram

DIAGNOSTIC_TEST

Trolley-Mounted Multifocal Skin-Electrode Electroretinography (Device to be evaluated)

UTAS multifocal electroretinogram

DIAGNOSTIC_TEST

Spectral-Domain Optical Coherence Tomography (Standard of Care test)

Heidelberg Engineering Spectralis Spectral-Domain Optical Coherence Tomography (macular structural scan)

DIAGNOSTIC_TEST

Macular Autofluorescence (Standard of Care test)

Heidelberg Engineering Spectralis Autofluorescence imaging (macular structural image)

Sponsors & Collaborators

  • LUPUS UK

    collaborator UNKNOWN

  • King's College Hospital Charity

    collaborator UNKNOWN

  • King's College Hospital NHS Trust

    lead OTHER

Principal Investigators

  • Professor Timothy L Jackson · King's College Hospital NHS Trust

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-31
Primary Completion
2026-05-31
Completion
2026-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06035887 on ClinicalTrials.gov